Literature DB >> 23395194

Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.

Paul B Rosenberg1, D F Wong, S L Edell, J S Ross, A D Joshi, J R Brašić, Y Zhou, V Raymont, A Kumar, H T Ravert, R F Dannals, M J Pontecorvo, D M Skovronsky, C G Lyketsos.   

Abstract

OBJECTIVE: To examine the association between regional brain uptake of a novel amyloid positron emission tomography (PET) tracer florbetapir F 18 ([(18)F]-AV-45) and cognitive performance in a pilot study.
DESIGN: Cross-sectional comparison of [(18)F]-AV-45 in AD patients versus controls.
SETTING: Three specialty memory clinics. PARTICIPANTS: Eleven participants with probable Alzheimer disease (AD) by NINDS/ADRDA criteria and 15 healthy comparison (HC) participants. MEASUREMENTS: Participants underwent PET imaging following a 370 MBq (10 mCi) intravenous administration of [(18)F]-AV-45. Regional/cerebellar standardized uptake value ratios (SUVRs) were calculated. Cognition was assessed using Mini-Mental State Examination, Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Wechsler Logical Memory IA (immediate recall) test (LMIA), and verbal category fluency.
RESULTS: Greater [(18)F]-AV-45 SUVR was associated with poorer performance on all cognitive tests. In the HC group, occipital, parietal, precuneus, temporal, and cortical average SUVR was associated with greater ADAS-Cog, and greater anterior cingulate SUVR was associated with lower LMIA. Two HC participants had [(18)F]-AV-45 cortical/cerebellar SUVR greater than 1.5, one of whom had deficits in episodic recall and on follow-up met criteria for amnestic mild cognitive impairment.
CONCLUSION: [(18)F]-AV-45 SUVR in several brain regions was associated with worse global cognitive performance particularly in HC, suggesting its potential as a marker of preclinical AD.
Copyright © 2013 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23395194      PMCID: PMC3711793          DOI: 10.1016/j.jagp.2012.11.016

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  21 in total

1.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.

Authors:  William J Jagust; Dan Bandy; Kewei Chen; Norman L Foster; Susan M Landau; Chester A Mathis; Julie C Price; Eric M Reiman; Daniel Skovronsky; Robert A Koeppe
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.

Authors:  Timo Grimmer; Gjermund Henriksen; Hans-Jürgen Wester; Hans Förstl; William E Klunk; Chester A Mathis; Alexander Kurz; Alexander Drzezga
Journal:  Neurobiol Aging       Date:  2008-03-17       Impact factor: 4.673

3.  Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB.

Authors:  S M Resnick; J Sojkova; Y Zhou; Y An; W Ye; D P Holt; R F Dannals; C A Mathis; W E Klunk; L Ferrucci; M A Kraut; D F Wong
Journal:  Neurology       Date:  2010-02-10       Impact factor: 9.910

4.  Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.

Authors:  Gaël Chételat; Victor L Villemagne; Pierrick Bourgeat; Kerryn E Pike; Gareth Jones; David Ames; Kathryn A Ellis; Cassandra Szoeke; Ralph N Martins; Graeme J O'Keefe; Olivier Salvado; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

5.  Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators.

Authors: 
Journal:  Alzheimer Dis Assoc Disord       Date:  2004 Jul-Sep       Impact factor: 2.703

6.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.

Authors:  Martha Storandt; Mark A Mintun; Denise Head; John C Morris
Journal:  Arch Neurol       Date:  2009-12

7.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

8.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

9.  Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

Authors:  A Okello; J Koivunen; P Edison; H A Archer; F E Turkheimer; K Någren; R Bullock; Z Walker; A Kennedy; N C Fox; M N Rossor; J O Rinne; D J Brooks
Journal:  Neurology       Date:  2009-07-08       Impact factor: 9.910

10.  Cognition, reserve, and amyloid deposition in normal aging.

Authors:  Dorene M Rentz; Joseph J Locascio; John A Becker; Erin K Moran; Elisha Eng; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

View more
  18 in total

1.  Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.

Authors:  Reisa A Sperling; Keith A Johnson; P Murali Doraiswamy; Eric M Reiman; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Alan Carpenter; Mat D Davis; Ming Lu; Matthew Flitter; Abhinay D Joshi; Christopher M Clark; Michael Grundman; Mark A Mintun; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  Neurobiol Aging       Date:  2012-08-09       Impact factor: 4.673

Review 2.  Advances in development of fluorescent probes for detecting amyloid-β aggregates.

Authors:  Ming-Ming Xu; Wen-Ming Ren; Xi-Can Tang; You-Hong Hu; Hai-Yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-03-21       Impact factor: 6.150

3.  Discrete Pools of Oligomeric Amyloid-β Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis.

Authors:  Angie C A Chiang; Stephanie W Fowler; Rohit Reddy; Olga Pletnikova; Juan C Troncoso; Mathew A Sherman; Sylvain E Lesne; Joanna L Jankowsky
Journal:  Am J Pathol       Date:  2017-12-15       Impact factor: 4.307

Review 4.  Amyloid imaging in Alzheimer's disease: a literature review.

Authors:  P Saidlitz; T Voisin; B Vellas; P Payoux; A Gabelle; M Formaglio; J Delrieu
Journal:  J Nutr Health Aging       Date:  2014-07       Impact factor: 4.075

5.  PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease.

Authors:  Michael J Pontecorvo; Mark A Mintun
Journal:  Alzheimers Res Ther       Date:  2011-03-29       Impact factor: 6.982

6.  Amyloid burden in the hippocampus and default mode network: relationships with gray matter volume and cognitive performance in mild stage Alzheimer disease.

Authors:  Ya-Ting Chang; Chi-Wei Huang; Yen-Hsiang Chang; Nai-Ching Chen; Kun-Ju Lin; Tzu-Chen Yan; Wen-Neng Chang; Sz-Fan Chen; Chun-Chung Lui; Pin-Hsuan Lin; Chiung-Chih Chang
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

7.  A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition.

Authors:  Effie M Mitsis; Heidi A Bender; Lale Kostakoglu; Josef Machac; Jane Martin; Jennifer L Woehr; Margaret C Sewell; Amy Aloysi; Martin A Goldstein; Clara Li; Mary Sano; Sam Gandy
Journal:  Mol Neurodegener       Date:  2014-02-03       Impact factor: 14.195

Review 8.  Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.

Authors:  Qingwei Ruan; Grazia D'Onofrio; Daniele Sancarlo; Zhijun Bao; Antonio Greco; Zhuowei Yu
Journal:  BMC Geriatr       Date:  2016-05-16       Impact factor: 3.921

9.  Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.

Authors:  Milos D Ikonomovic; Chris J Buckley; Kerstin Heurling; Paul Sherwin; Paul A Jones; Michelle Zanette; Chester A Mathis; William E Klunk; Aruna Chakrabarty; James Ironside; Azzam Ismail; Colin Smith; Dietmar R Thal; Thomas G Beach; Gill Farrar; Adrian P L Smith
Journal:  Acta Neuropathol Commun       Date:  2016-12-12       Impact factor: 7.801

10.  A systems-biology clinical trial of a personalized multimodal lifestyle intervention for early Alzheimer's disease.

Authors:  Sarah C McEwen; David A Merrill; Jennifer Bramen; Verna Porter; Stella Panos; Scott Kaiser; John Hodes; Aarthi Ganapathi; Lesley Bell; Tess Bookheimer; Ryan Glatt; Molly Rapozo; Mary Kay Ross; Nathan D Price; Daniel Kelly; Cory C Funk; Leroy Hood; Jared C Roach
Journal:  Alzheimers Dement (N Y)       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.